Lymphedema Treatment Market size was over USD 0.7 billion in 2024 and is estimated to reach USD 1.7 billion by the end of 2037, expanding at a CAGR of 7.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of lymphedema treatment is evaluated at USD 0.7 billion.
The market is experiencing remarkable growth due to the increased risk of prevalence due to growing cancer cases. Surgical or, radiational treatments for cancers such as breast, prostate, and melanoma often result in removal or, damage of lymph nodes, causing this condition. According to an NLM article, published in October 2022, the point incidence of breast cancer associated lymphedema was accounted for 6.8% at baseline. It was followed by 19.9% and 23.8% at two- and seven-years post diagnosis respectively. It indicates the co-relation of this sector’s expansion with the inflating demand for effective treatment for lymphedema. In addition, it is often directed to the symptoms of blood cancer, which contributes to the surge for management solutions.
The frequent events of cancer-related surgical and radiational interventions are raising the demand for pre-hand solution availability, propelling the lymphedema treatment market. This is further inspiring pharmaceutical and therapeutic companies to develop new treatment methods and medications to restore and protect the lymphatic system. They are participating in strategic collaborations to globalize their product pipeline. For instance, in October 2022, ImpediMed Limited signed a global commercial partnership with GenesisCare to launch the Lymphedema Prevention Program in the U.S. for cancer survivors. The pilot program is dedicated to enroll breast cancer patients for lymphedema screening services across the country by establishing five (5) SOZO units initially.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.8% |
|
Base Year Market Size (2024) |
USD 0.7 billion |
|
Forecast Year Market Size (2037) |
USD 1.7 billion |
|
Regional Scope |
|
Type (Primary Lymphedema, Secondary Lymphedema)
The secondary lymphedema segment is set to account for around 68.1% lymphedema treatment market share by 2037. The major cause of this type of condition is the breast cancer, which is increasing in prevalence each year. According to an article published in March 2023, around 50% of the breast cancer patients, having axillary lymph node dissection are estimated to develop lymphedema. Around 75% of the cases occurs within one year after the surgery, which require serious medical attention. In this developed world, it has become a necessity to incorporate proper management and preventive measures in patient care related to such female prone diseases. Thus, the demand for effective treatment in this segment is rising.
Affected Area (Lower Extremity, Upper Extremity, Genitalia)
Based on affected area, the lymphedema treatment market is estimated to earn a notable amount of profit for the lower extremity segment during the forecast period. Contribution to the disruption in the crucial part of regular mobility puts this segment on the prime focus of patients to seek treatment for. In addition, a majority of lymphedema (LE) cases are registered with a complaint of swelling in legs and feet, raising demand for treatment. The variety in options such as compression garments & stockings, manual lymphatic drainage & physiotherapy, pneumatic compression devices, and surgical procedures also makes it lucrative for the global leaders. For instance, in April 2022, Koya Medical announced the commercial launch of Dayspring active compression system for lower extremity lymphedema.
Our in-depth analysis of the global lymphedema treatment market includes the following segments:
|
Type |
|
|
Affected Area |
|
|
Treatment |
|
|
End user |
|
North America Market Analysis
In lymphedema treatment market, North America region is likely to hold more than 52.9% revenue share by 2037. The major growth factor of this region is the growing prevalence of such chronic conditions due to various reasons including cancer treatment, surgeries, and genetic disorders. According to a report published by the NLM, in September 2024, around 10 million people in the U.S. and 1 million people in Canada are suffering from LE. These issues are rising primarily due to lymphatic dysfunction or malformations. The governing bodies in this region are proactively promoting the available treatment options through arranging campaigns and building supportive advocacy groups, propelling the sector.
The U.S. is leading the regional growth in the lymphedema treatment market with its strong emphasis on medical industry. The country is predominantly establishing an adequate public healthcare setting, equipped with specially trained professionals and innovative therapeutic solutions. For instance, in March 2024, Bay Pines VA Healthcare System, a crucial organization of the U.S. Department of Veterans Affairs commenced an Occupational Therapy Lymphedema Fellowship. The program enabled the licensed occupational therapists across the country to gain immense knowledge about this condition through its one-year long paid fellowship.
Canada is pioneering opportunities for the participants in the lymphedema treatment market to endeavor their options to generate profitable revenue with regulatory support. It is meticulously improving clinical practices across the country to bring out the best management and treatment facilities for patients. This is further inspiring the global leaders to participate in this landscape. For instance, in January 2021, the government of Ontario issued Assistive Devices Program (ADP) to help patients pay for compression garments, lymphedema pumps, and custom orthotic braces. Such financial support is further encouraging more consumers to invest in this sector.
APAC Market Statistics
The Asia Pacific lymphedema treatment market poised to register the fastest growth in the global landscape during the forecast period, i.e. 2025-2037. The region is highly influenced by the Increased R&D projects to discover more effective techniques and methods are broadening the range of offerings. The cumulative burden of LE incidences is inflating demand in this sector, creating a large consumer base for this sector. The growing economy of this region is a major contributor to the healthcare advancements, such as introduction of treatment for such niche medical categories. According to a WHO report, published in December 2024, the number of registered clinical trials in Western Pacific reached 23,250 in 2023, making it the highest scorer among the WHO regions.
India lymphedema treatment market is fostering a lucrative trading environment for both global and domestic pharma leaders. The exceptional growth in the pharmaceutical industry of this country is notably fueling this sector. It is further utilizing this as a USP in controlling the widespread of such lymphatic conditions. For instance, in August 2024, the 2nd phase of Bi-annual Nationwide Mass Drug Administration (MDA) campaign to fight against lymphatic filariasis, a major cause of lymphedema was launched. This program planned to roll-out preventive measures and medication across 63 districts and 771 blocks in 6 states of India.
China is utilizing its R&D and manufacturing capabilities to lead the regional growth in the lymphedema treatment market. The continuous government fundings, university projects, and hospital demand are accumulatively supporting the country’s ambitious goal in pharmaceutical developments. This is further accelerating its progress in this sector. According to a WHO data, released in December 2024, China topped among the Western Pacific countries in clinical trial registration. In 2024, the country achieved a total 135,747 number of trials, capturing a 14.9% of the global amount.
The global lymphedema treatment market is propagating towards great medical achievements through the R&D efforts made by the global leaders. They are playing a pivotal role in broadening product reach of this sector, widening applications and consumer base. They are also taking part in promoting the effectiveness of the available treatments by participating in campaigns and programs. This is further helping them cultivate positive consumer feedback for their portfolio. For instance, in September 2024, Koya Medical announced the results of the clinical study on Dayspring for lower extremity lymphedema, TEAYS. It highlighted the reduction in limb volume by 369.9 mL and 81% adherence rate in the APCD treatment arm. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?